Tolerability, Adherence and Completion of New Occupational HIV Post-Exposure Prophylaxis Regimens (Tenofovir + Emtricitabine and Raltegravir)
Methods: In this retrospective case control study, we reviewed the charts of 160 employees at risk for HIV infection due to occupational exposure at Montefiore Medical Center in the Bronx NY from 2007-2013. We assessed risk of the exposure, initial PEP regimen, changes in regimen, rates of completion, costs, and side effects due to medications.
Results: Of the 160 employees, 153 had initial and follow-up information. Of these, 93 initially started on zidovudine + lamivudine and lopinavir/ritonavir (ZDV/3TC/LPV) were compared to 48 initially started on TNF/FTC/RAL. 40 of 93 (43%) of those in the ZDV/3TC/LPV group completed 4 weeks of therapy versus 31 of 48 (65%) of those in the TNF/FTC/RAL group (p=0.015). 68 of 93 (73%) of employees receiving ZDV/3TC/LPV reported side effects, compared to 27 of 48 (56%) of those receiving TNF/FTC/RAL (p=0.043). Further analyses will be presented at the meeting.
Conclusion: Employees receiving tenofovir + emtricitabine and raltegravir for occupational HIV post-exposure prophylaxis were more likely to complete the recommended 4 week course of therapy, and reported fewer side effects than those who received the prior recommended regimen of zidovudine + lamivudine and lopinavir/ritonavir. Tenofovir + emtricitabine and raltegravir appears to be superior to older regimens in key parameters critical to the success of occupational PEP programs.
M. Catalano, None
S. Hacker, None
B. Zingman, None